Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis

Arthritis and Rheumatism

Volumn 46, Issue 10, 2002, Pages 2604-2612

  Coxon, Angela ^a   Bolon, Brad ^a   Estrada, Juan ^a   Kaufman, Stephen ^a   Scully, Sheila ^a   Rattan, Alana ^a   Duryea, Diane ^a   Hu, Yi Ling ^a   Rex, Karen ^a   Pacheco, Efrain ^a   Van, Gwyneth ^a   Zack, Debra ^a   Feige, Ulrich ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGSUNERCEPT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSAY; CAPILLARY; CONTROLLED STUDY; CORNEA; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FEMALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SCORING SYSTEM;

EID: 0036822909     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10546     Document Type: Article

References (50)

1. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
2. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998;20:133-47.
3. Brennan FM, Field M, Chu CQ, Feldmann M, Maini RN. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991;30 Suppl 1:76-80.
4. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
5. Richard-Miceli C, Dougados M. Tumour necrosis factor-α blockers in rheumatoid arthritis: review of the clinical experience. BioDrugs 2001;15:251-9.
6. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
7. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, et al. Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 1993;11:515-22.
8. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
9. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-14.
10. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
11. Kuiper S, Joosten LA, Bendele AM, Edwards CK III, Arntz OJ, Helsen MM, et al. Different roles of tumour necrosis factor α and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
12. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B, Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000;57:1457-70.
13. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992;6:2591-9.
14. Fan TP, Hu DE, Guard S, Gresham GA, Watling KJ. Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol 1993;110:43-9.
15. Dana MR, Zhu SN, Yamada J, Topical modulation of interleukin-1 activity in corneal neovascularization, Cornea 1998;17:403-9.
16. Fràter-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 1987;84:5277-81.
17. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987;329:630-2.
18. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNFα antibody in rheumatoid arthritis. Mol Pathol 1997;50:225-33.
19. Qian Y, Dekaris I, Yamagami S, Dana MR. Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol 2000;118:1666-71.
20. Walsh DA, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001;3:147-53.
21. Buma P, Groenenberg M, Rijken PF, van den Berg WB, Joosten L, Peters H. Quantitation of the changes in vascularity during arthritis in the knee joint of a mouse with a digital image analysis system. Anat Rec 2001;262:420-8.
22. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
23. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175:1135-8.
24. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995;166:196-206.
25. Lu J, Kasama T, Kobayashi K, Yoda Y, Shiozawa F, Hanyuda M, et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 2000;164:5922-7.
26. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
27. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A, Shimano H, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001;281:562-8.
28. Peacock DJ, Banquerigo ML, Brahn E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 1995;160:178-84.
29. 3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:128-37.
30. Polverini PJ, Cotran PS, Gimbrone MA Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature 1977;269:804-6.
31. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-32.
32. Wilkinson DG. In situ hybridization: a practical approach. Oxford (UK): IRL Press; 1993.
33. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32:1065-73.
34. Matsubara T, Saura R, Hirohata K, Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 1989;83:158-67.
35. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
36. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem (Tokyo) 1998;123:431-9.
37. Detmar M, Tenorio S, Hettmannsperger U, Ruszczak Z, Orfanos CE. Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 1992;98:147-53.
38. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
39. Maeno N, Takei S, Imanaka H, Takasaki I, Kitajima I, Maruyama I, et al. Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis. J Rheumatol 1999;26:2244-8.
40. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
41. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
42. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y, Irisa T, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002;168:450-7.
43. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995;22:1624-30.
44. Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β. J Rheumatol 1997;24:1253-9.
45. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101.
46. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-9.
47. Cozzolino F, Torcia M, Aldinucci D, Ziche M, Almerigogna F, Bani D, et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci U S A 1990;87:6487-91.
48. Van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001;30:7-16.
49. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 1995;136:3054-61.
50. Xu LX, Kukita T, Nakano Y, Yu H, Hotokebuchi T, Kuratani T, et al. Osteoclasts in normal and adjuvant arthritis bone tissues express the mRNA for both type I and II interleukin-1 receptors. Lab Invest 1996;75:677-87.